CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT03409432
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:32.896540+00:00
Published At: 2025-07-25T00:00:00+00:00
Record Updated At: 2025-07-25
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Lymphomatoid Papulosis", "Primary Cutaneous Anaplastic Large Cell Lymphoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-07-25"
protocolSection.identificationModule.nctId: "NCT03409432"
protocolSection.identificationModule.officialTitle: "A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.